NMS Capital has promoted Daniel Schwartz to managing director and Jake Kinsley to vice president. Schwartz joined NMS in 2021 as a principal while Kinsley came on board in 2018 as an associate. New ...

Neuroleptic malignant syndrome (NMS) is a rare reaction to antipsychotic drugs that are used to treat schizophrenia, bipolar disorder, and other mental health conditions. It affects the nervous system ...

NMS Capital has recapitalized Center for Social Dynamics Inc, an applied behavioral analysis services company that specializes in treating autism spectrum disorder. No financial terms were disclosed.

LOS ANGELES, CA / ACCESS Newswire / May 12, 2025 / NMS Capital Group ("NMS") is proud to announce its inclusion in the Los Angeles Business Journal's 2024 list of Top Private Equity Firms, published ...

Axiom, founded in 1999 and based in The Woodlands, Texas, is a workplace incident case management solutions provider focused on self-insured employers. NMS, founded in 2010 and based in New York, is a ...

WE REPORT A CASE INVOLVING AN 81-YEAR-OLD man with schizoaffective disorder who presented with neuroleptic malignant syndrome (NMS) after an increase in his neuroleptic dose. NMS, a rare but ...

HORSHAM, Pa.--(BUSINESS WIRE)--NMS Labs announced today that David Delia has been selected as the new President and Chief Executive Officer of the Company. Mr. Delia will guide the organization’s ...